drugset / Trial / NCT04371445

Dextenza in the Post-op Management of Vitreoretinal Surgeries

NCT04371445 ↗

RandomizedParallel-groupSingle-blindPrevention

Summary

This study will assess the control of inflammation at days 1, 7, 14, and 21 days following the vitreoretinal surgical procedure analyzing two randomized study arms: Intracanalicular dexamethasone insert group or topical steroid drop group. Patients must be 18 years of age and older, of any race and either sex, requiring surgery with the procedure type of pars plana vitrectomy for either the indication of macular hole, epiretinal membrane removal, or vitreomacular traction.

Timeline

Start
2020-06-01
Primary completion
2026-05-01
Completion
2026-05-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 0.4 mg Other
Comparator Prednisolone Other / unclassified 1 % Topical

Indications

No indication recorded.